JPRN-UMIN000008848已完成未知
Phase 1/2 study of weekly paclitaxel and gemcitabine in patient with HER2 negative recurrent breast cancer - Phase 1/2 study of weekly paclitaxel and gemcitabine in patient with HER2 negative recurrent breast cance
Hiroshima Breast Cancer Study Group0 个研究点目标入组 45 人开始时间: 2012年9月4日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •*Her2 positive *Prior administration of gemcitabine *Pulmonary fibrosis or pneumonitis *Abnormal cardiac function, myocardial infarction within 6 months *Body cavity fluid which needs to treatment *Active infection *Severe complicated situation *Severe drug allergic reaction *Serious psychiatric illness *After bone marrow transplantation *After stem cell transplantation *Symptomatic systemic brain metastasis *Active double cancer *Double chemotherapy *Pregnancy, breast feeding, suspected pregnancy
研究者
相似试验
已完成
2 期
A phase 2 study of weekly Paclitaxel plus Gemcitabine Combination Chemotherapy in Patients with advanced or metastatic Breast CancerBreast CancerJPRN-UMIN000004741Kinki Multidisciplinary Breast Oncology Group35
未知
2 期
Phase II study of a combined Paclitaxel, Gemcitabine, and Cisplatin chemotherapy regimen for advanced urothelial carcinomaadvanced urothelial carcinomaJPRN-UMIN000001979Cancer Institute Hospital, Japanese Foundation for Cancer Research30
已完成
不适用
Phase1 trial of weekly paclitaxel and gemcitabine in previously anthracycline-treated patients with locally advanced or metastatic breast cancer (SBCCSG-17)Breast CancerJPRN-UMIN000004084Saitama Breast Cancer Clinical Study Group(SBCCSG)12
已完成
2 期
A combination phase II study of paclitaxel and gemcitabine for recurrent or relapsed non-small cell lung cancer previously treated with platinum or docetaxel-based regimenon-small cell lung cancerJPRN-C000000219West Japan Oncology Group80
已完成
不适用
A phase II study of gemcitabine and nab-paclitaxel followed by chemoradiotherapy with S-1 in patients with locally advanced pancreatic cancerJPRN-UMIN000026525Chiba Cancer Center30